TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features

Keith Anthony Josephs, Jennifer Lynn Whitwell, Nirubol Tosakulwong, Stephen D. Weigand, Melissa E Murray, Amanda M. Liesinger, Leonard Petrucelli, Matthew L. Senjem, Robert J. Ivnik, Joseph E Parisi, Ronald Carl Petersen, Dennis W Dickson

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective The aim of this study was to determine whether the frequency of TAR DNA-binding protein 43 (TDP-43) deposition in Alzheimer's disease (AD) differs across pathologically defined AD subtypes (hippocampal sparing [HpSp]; typical and limbic) and further examine the relationship between TDP-43, pathological subtype, and clinical features in AD. Methods We identified all cases with pathologically confirmed AD (NIA-Reagan intermediate-high probability, Braak stage IV-VI) independent of cognitive status (n = 188). Neurofibrillary tangle counts were performed using thioflavin-S microscopy in hippocampus and three neocortical regions, and all cases were subtyped: HpSp AD pathology (n = 19); typical AD pathology (n = 136); and limbic AD pathology (n = 33). TDP-43 immunoreactivity was performed in multiple brain regions to assess for the presence of TDP-43 and TDP-43 stage. All cases were clinically subclassified at presentation as amnestic AD dementia versus atypical AD dementia. Statistical analysis was performed using linear and penalized logistic regression to assess associations with pathological subtype, and the effects of TDP-43, accounting for possible interactions between pathological subtype and TDP-43. Results TDP-43 deposition was frequent in typical (59%) and limbic AD pathologies (67%), but not HpSp AD pathology (21%; p = 0.003). The observed associations of TDP-43 with greater memory loss, naming and functional decline, and smaller hippocampal volumes, closest to death, did not differ across AD pathological subtype. Clinical presentation was associated with pathological subtype (p = 0.01), but not TDP-43 (p = 0.69). Interpretation Although the frequency of TDP-43 deposition in AD varies by pathological subtype, the observed effects of TDP-43 on clinical/magnetic resonance imaging features are consistent across pathological subtypes. Clinical presentation in AD is driven by pathological subtype, not by TDP-43.

Original languageEnglish (US)
Pages (from-to)697-709
Number of pages13
JournalAnnals of Neurology
Volume78
Issue number5
DOIs
StatePublished - Nov 1 2015

Fingerprint

DNA-Binding Proteins
Alzheimer Disease
Pathology
Neurofibrillary Tangles
Memory Disorders

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. / Josephs, Keith Anthony; Whitwell, Jennifer Lynn; Tosakulwong, Nirubol; Weigand, Stephen D.; Murray, Melissa E; Liesinger, Amanda M.; Petrucelli, Leonard; Senjem, Matthew L.; Ivnik, Robert J.; Parisi, Joseph E; Petersen, Ronald Carl; Dickson, Dennis W.

In: Annals of Neurology, Vol. 78, No. 5, 01.11.2015, p. 697-709.

Research output: Contribution to journalArticle

Josephs, Keith Anthony ; Whitwell, Jennifer Lynn ; Tosakulwong, Nirubol ; Weigand, Stephen D. ; Murray, Melissa E ; Liesinger, Amanda M. ; Petrucelli, Leonard ; Senjem, Matthew L. ; Ivnik, Robert J. ; Parisi, Joseph E ; Petersen, Ronald Carl ; Dickson, Dennis W. / TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. In: Annals of Neurology. 2015 ; Vol. 78, No. 5. pp. 697-709.
@article{0f40b7d02cda4cf083ef84a0e30210ee,
title = "TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features",
abstract = "Objective The aim of this study was to determine whether the frequency of TAR DNA-binding protein 43 (TDP-43) deposition in Alzheimer's disease (AD) differs across pathologically defined AD subtypes (hippocampal sparing [HpSp]; typical and limbic) and further examine the relationship between TDP-43, pathological subtype, and clinical features in AD. Methods We identified all cases with pathologically confirmed AD (NIA-Reagan intermediate-high probability, Braak stage IV-VI) independent of cognitive status (n = 188). Neurofibrillary tangle counts were performed using thioflavin-S microscopy in hippocampus and three neocortical regions, and all cases were subtyped: HpSp AD pathology (n = 19); typical AD pathology (n = 136); and limbic AD pathology (n = 33). TDP-43 immunoreactivity was performed in multiple brain regions to assess for the presence of TDP-43 and TDP-43 stage. All cases were clinically subclassified at presentation as amnestic AD dementia versus atypical AD dementia. Statistical analysis was performed using linear and penalized logistic regression to assess associations with pathological subtype, and the effects of TDP-43, accounting for possible interactions between pathological subtype and TDP-43. Results TDP-43 deposition was frequent in typical (59{\%}) and limbic AD pathologies (67{\%}), but not HpSp AD pathology (21{\%}; p = 0.003). The observed associations of TDP-43 with greater memory loss, naming and functional decline, and smaller hippocampal volumes, closest to death, did not differ across AD pathological subtype. Clinical presentation was associated with pathological subtype (p = 0.01), but not TDP-43 (p = 0.69). Interpretation Although the frequency of TDP-43 deposition in AD varies by pathological subtype, the observed effects of TDP-43 on clinical/magnetic resonance imaging features are consistent across pathological subtypes. Clinical presentation in AD is driven by pathological subtype, not by TDP-43.",
author = "Josephs, {Keith Anthony} and Whitwell, {Jennifer Lynn} and Nirubol Tosakulwong and Weigand, {Stephen D.} and Murray, {Melissa E} and Liesinger, {Amanda M.} and Leonard Petrucelli and Senjem, {Matthew L.} and Ivnik, {Robert J.} and Parisi, {Joseph E} and Petersen, {Ronald Carl} and Dickson, {Dennis W}",
year = "2015",
month = "11",
day = "1",
doi = "10.1002/ana.24493",
language = "English (US)",
volume = "78",
pages = "697--709",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features

AU - Josephs, Keith Anthony

AU - Whitwell, Jennifer Lynn

AU - Tosakulwong, Nirubol

AU - Weigand, Stephen D.

AU - Murray, Melissa E

AU - Liesinger, Amanda M.

AU - Petrucelli, Leonard

AU - Senjem, Matthew L.

AU - Ivnik, Robert J.

AU - Parisi, Joseph E

AU - Petersen, Ronald Carl

AU - Dickson, Dennis W

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Objective The aim of this study was to determine whether the frequency of TAR DNA-binding protein 43 (TDP-43) deposition in Alzheimer's disease (AD) differs across pathologically defined AD subtypes (hippocampal sparing [HpSp]; typical and limbic) and further examine the relationship between TDP-43, pathological subtype, and clinical features in AD. Methods We identified all cases with pathologically confirmed AD (NIA-Reagan intermediate-high probability, Braak stage IV-VI) independent of cognitive status (n = 188). Neurofibrillary tangle counts were performed using thioflavin-S microscopy in hippocampus and three neocortical regions, and all cases were subtyped: HpSp AD pathology (n = 19); typical AD pathology (n = 136); and limbic AD pathology (n = 33). TDP-43 immunoreactivity was performed in multiple brain regions to assess for the presence of TDP-43 and TDP-43 stage. All cases were clinically subclassified at presentation as amnestic AD dementia versus atypical AD dementia. Statistical analysis was performed using linear and penalized logistic regression to assess associations with pathological subtype, and the effects of TDP-43, accounting for possible interactions between pathological subtype and TDP-43. Results TDP-43 deposition was frequent in typical (59%) and limbic AD pathologies (67%), but not HpSp AD pathology (21%; p = 0.003). The observed associations of TDP-43 with greater memory loss, naming and functional decline, and smaller hippocampal volumes, closest to death, did not differ across AD pathological subtype. Clinical presentation was associated with pathological subtype (p = 0.01), but not TDP-43 (p = 0.69). Interpretation Although the frequency of TDP-43 deposition in AD varies by pathological subtype, the observed effects of TDP-43 on clinical/magnetic resonance imaging features are consistent across pathological subtypes. Clinical presentation in AD is driven by pathological subtype, not by TDP-43.

AB - Objective The aim of this study was to determine whether the frequency of TAR DNA-binding protein 43 (TDP-43) deposition in Alzheimer's disease (AD) differs across pathologically defined AD subtypes (hippocampal sparing [HpSp]; typical and limbic) and further examine the relationship between TDP-43, pathological subtype, and clinical features in AD. Methods We identified all cases with pathologically confirmed AD (NIA-Reagan intermediate-high probability, Braak stage IV-VI) independent of cognitive status (n = 188). Neurofibrillary tangle counts were performed using thioflavin-S microscopy in hippocampus and three neocortical regions, and all cases were subtyped: HpSp AD pathology (n = 19); typical AD pathology (n = 136); and limbic AD pathology (n = 33). TDP-43 immunoreactivity was performed in multiple brain regions to assess for the presence of TDP-43 and TDP-43 stage. All cases were clinically subclassified at presentation as amnestic AD dementia versus atypical AD dementia. Statistical analysis was performed using linear and penalized logistic regression to assess associations with pathological subtype, and the effects of TDP-43, accounting for possible interactions between pathological subtype and TDP-43. Results TDP-43 deposition was frequent in typical (59%) and limbic AD pathologies (67%), but not HpSp AD pathology (21%; p = 0.003). The observed associations of TDP-43 with greater memory loss, naming and functional decline, and smaller hippocampal volumes, closest to death, did not differ across AD pathological subtype. Clinical presentation was associated with pathological subtype (p = 0.01), but not TDP-43 (p = 0.69). Interpretation Although the frequency of TDP-43 deposition in AD varies by pathological subtype, the observed effects of TDP-43 on clinical/magnetic resonance imaging features are consistent across pathological subtypes. Clinical presentation in AD is driven by pathological subtype, not by TDP-43.

UR - http://www.scopus.com/inward/record.url?scp=84945477559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945477559&partnerID=8YFLogxK

U2 - 10.1002/ana.24493

DO - 10.1002/ana.24493

M3 - Article

C2 - 26224156

AN - SCOPUS:84945477559

VL - 78

SP - 697

EP - 709

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 5

ER -